RE:Moving to Nasdaq and market valuationOne other point about your so-called comparisons. Neither of the companies you hand picked are DMT/Psychedelic companies. Nor is either company investigating Chronic Cough. The comparisons I listed are companies that are actually in the exact same category for treatments. Your analogies are therefore poorly lacking. Everyone paying attention knows the Psychedelic sector is just getting heated up. Billions are waiting on the sidelines for legitimate startups to come to the forefront. A move to Nasdaq for Algernon will expose it to those billion dollar money streams sitting on the sidelines. You are proving yourself to not know much in at least a couple places you frequently post on Stockhouse, but don't let any facts get in your way.